Literature DB >> 20236752

Renin-angiotensin system dysregulation in fetuses with hydronephrosis.

Aikaterini Stipsanelli1, George Daskalakis, Panagiota Koutra, Angeliki Tsaroucha, Evangelia Kounadi, Vassilios Papantoniou, Aris Antsaklis.   

Abstract

OBJECTIVES: To evaluate if fetal hydronephrosis is associated with dysregulation of the renin-angiotensin system (RAS), and if it could represent an early predictor of future renal damage or arterial hypertension. STUDY
DESIGN: The study consisted of 26 pregnant women and their fetuses. Ultrasound scans were performed to evaluate the renal pelvis in fetuses. Four fetuses with hydronephrosis were included in the study, while the rest were found to have normal renal pelvis. Active and inactive renin was calculated by IRMA method in fetal and maternal blood, during the second trimester of pregnancy.
RESULTS: A comparison of plasma active and inactive renin levels was made between pregnant women and their fetuses, as well as between fetuses with and without hydronephrosis. Active and inactive renin levels obtained from fetuses with hydronephrosis were significantly higher compared to those obtained from fetuses with normal kidneys.
CONCLUSIONS: Dilatation of renal pelvis in the second trimester of pregnancy seems to up-regulate the renin and prorenin system in fetal blood. Both factors are indicative of possible future renal pathology. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20236752     DOI: 10.1016/j.ejogrb.2010.02.031

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  1 in total

1.  The role of Plasma Renin Activity in prenatally diagnosed non-obstructed hydronephrosis at risk for surgery-an observational study.

Authors:  Minu Bajpai; Kanika Sharma; Siddharth Kapahtia; Pradeep K Chaturvedi; Rakesh Kumar; Manisha Jana; Sada N Dwivedi
Journal:  J Nephrol       Date:  2022-02-07       Impact factor: 3.902

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.